LXEO insider trading
NasdaqGM HealthcareLexeo Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Company website: www.lexeotx.com
LXEO insider activity at a glance
FilingIQ has scored 96 insider transactions for LXEO since Nov 7, 2023. The most recent filing in our index is dated Apr 28, 2026.
Across the full history, 4 open-market purchases
and 45 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LXEO insider trades is 52.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for LXEO?
- FilingIQ tracks 96 Form 4 insider transactions for LXEO (Lexeo Therapeutics, Inc.), covering filings from Nov 7, 2023 onwards. 6 of those were filed in the last 90 days.
- Are LXEO insiders net buyers or net sellers?
- Across the full Form 4 history for LXEO, 4 transactions (4%) were open-market purchases and 45 (47%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LXEO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LXEO in?
- Lexeo Therapeutics, Inc. (LXEO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $459.09M.
Methodology & sources
Every LXEO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.